Niacin therapy: An evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol
University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637-5415, USA. The American Journal of Cardiology
(Impact Factor: 3.28).
05/2008; 101(8A):1B-2B. DOI: 10.1016/j.amjcard.2008.02.025
Available from: Jeffrey Bland
Alternative therapies in health and medicine 01/2008; 14(5):12-4. · 1.24 Impact Factor
Available from: Moti L Kashyap
[Show abstract] [Hide abstract]
ABSTRACT: To summarise the metabolic responses to niacin that can lead to flushing and to critically evaluate flushing mitigation research.
This comprehensive review of the mechanism of action of niacin-induced flushing critically evaluates research regarding flushing mitigating formulations and agents. Niacin induces flushing through dermal Langerhans cells where the activation of G protein-coupled receptor 109A (GPR109A) increases arachidonic acid and prostaglandins, such as prostaglandin D(2) (PGD(2)) and prostaglandin E(2) (PGE(2)), subsequently activating prostaglandin D(2) receptor (DP(1)), prostaglandin E(2) receptor (EP(2)) and prostaglandin E receptor 4 (EP(4)) in capillaries and causing cutaneous vasodilatation. Controlling niacin absorption rates, inhibiting prostaglandin production, or blocking DP(1), EP(2) and EP(4) receptors can inhibit flushing. Niacin extended-release (NER) formulations have reduced flushing incidence, duration and severity relative to crystalline immediate-release niacin with similar lipid efficacy. Non-steroidal anti-inflammatory drugs (NSAIDs), notably aspirin given 30 min before NER at bedtime, further reduce flushing. An antagonist to the DP(1) receptor (laropiprant) combined with an ER niacin formulation can reduce flushing; however, significant residual flushing occurs with clinically-relevant dosages.
Niacin is an attractive option for treating dyslipidemic patients, and tolerance to niacin-induced flushing develops rapidly. Healthcare professionals should particularly address flushing during niacin dose titration.
International Journal of Clinical Practice 10/2009; 63(9):1369-77. DOI:10.1111/j.1742-1241.2009.02099.x · 2.57 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.